August 28, 2015

Dear Manufacturers,

I am writing on behalf of North Central Bronx Hospital, 340B ID DSH330385, to inform manufacturers that North Central Bronx Hospital recently underwent an audit by the Health Resources and Services Administration (HRSA) of North Central Bronx Hospital's compliance with 340B Drug Pricing Program (340B) requirements.

As background, North Central Bronx Hospital qualified for the 340B Program as a Disproportionate Share Hospital at 3424 Kossuth Avenue, Bronx, New York 10467, and has participated in the 340B Program since 1992.

Through the audit process, North Central Bronx Hospital was found to have non-compliance within their 340B Program and responsible for repayment as a result of the following findings:

North Central Bronx Hospital dispensed 340B drugs to ineligible individuals, as prohibited by 42 USC 256b(a)(5)(B).

North Central Bronx Hospital's contract pharmacies incorrectly deemed two prescriptions 340B-eligible.

North Central Bronx Hospital reversed the 2 prescriptions from contract pharmacies that should not have been eligible.

North Central Bronx Hospital Center has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from North Central Bronx Hospital and believe repayment may be owed for the violation described in this letter, or if you have any questions or comments regarding the violation described in this letter, within the next 90 days from the date of this letter, please contact Mr. Paul A. Albertson, Sr. Assistant Vice President, Supply Chain Services, New York City Health and Hospitals Corporation, 160 Water Street, 13<sup>th</sup> Floor, New York, NY 10038, telephone number 212-748-2256, email: <a href="mailto:paul.albertson@nychhc.org">paul.albertson@nychhc.org</a>

Sincerely yours,

Antonio D. Martin